Beta-adrenergic receptor blockers as therapy in pediatric chronic heart failure

Minerva Pediatrica

Volumn 53, Issue 4, 2001, Pages 297-304

  Shaddy, R E ^a  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

Adrenergic beta antagonists; Cardiomyo pathy, congestive; Child; Heart failure, congestive, drug therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; PLACEBO;

CHILD; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HEART LEFT RIGHT SHUNT; HEART VENTRICLE FUNCTION; HUMAN; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CHILD; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0034782665     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Waagstein F, Hjalmarson A, Varauskas E. Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
2. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995;274:1462-7.
3. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40.
4. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
5. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P et al. Comparative hemodynamic, left ventricular functional, and antiadrencrgic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
6. Eichorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA et al. Effect of metoprolol on myo cardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-20.
7. Feuerstein GZ, Bril A, Ruffolo RR, Jr. Protective effects of carvedilol in the myocardium. Am J Carcliol 1997;80:41L-5.
8. Goldsmith RL, Bigger JT, Bloomfield DM, Krum H, Steinman RC, Sackner-Bernstein J et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol l997;80:1101-4.
9. Ohlstein EH, Douglas SA, Sung CP, Yue TL, Louden C, Arleth A et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189-93.
10. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunologic function. Circulation 1994;90:1774-80.
11. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-90.
12. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB. Deitchman D, Yanowitz FG et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
13. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
14. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin NIL, Schwartz B, Penn J et al. Double-blind, placebocontrolled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
15. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-6.
16. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
17. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
18. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997;79:794-8.
19. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
20. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBLS). CIBIS Investigators and Committees. Circulation 1994;90: 1765-73.
21. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators [comment] [see comments]. Circulation 1996;94:2807-16.
22. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
23. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey W. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999;33:924-31.
24. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344: 1651-8.
25. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol 2001;37:1692-9.
26. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
27. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
28. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102: 546-51.
29. Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation 2000;102: 484-6.
30. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995;129.197-9.
31. Shaddy RE. Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 1998;136:19-21.
32. Shaddy R, Tani L, Gidding S, Pahl E, Orsmond G, Gilbert E et al. Beta-blocker treatment of dilated cardiomyopathy in children: a multi-institutional experience. J Heart Lung Transplant 1999;18:269-74.
33. Buchhorn R, Bartmus D, Siekmeyer W, Hulpke-Wette M, Schuiz K, Bursch J. Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts. Am J Cardiol 1998;81:1366-8.
34. Buchhorn R, Hulpke-Wette M, Hilgers R, Bartmus D, Wessel A, Bursch J. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Int J Cardiol 2001;79: 167-73.
35. Buchhorn R, Ross RD, Hulpke-Wette M, Bartmus D, Wessel A, Schulz R et al. Effectiveness of low dose captopril versus propranolol therapy in infants with severe congestive failure due to left-to-right shunts. Int J Cardiol 2000;76:227-33.
36. Bruns LA, Chrisant MIC, Lamour JM, Shaddy RE, Pahl E, Blume ED et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001;138:505-11.
37. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow IVM. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol 1998;81:247-50.
38. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure [see comments]. J Am Coll Cardiol 1998;31:1336-40.
39. Richards AM, Doughty R, Nicholls MG, Macmalion S, Ikram H, Sharpe NJ et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999;99:786-92.
40. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999;33:916-23.
41. Frishman YM. Carvedilol. N Engl J Med 1998;339: 1759-65.
42. Packer M, Cohn J. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A-38.
43. Olsen S, Blank D, Taylor D. Gilbert E, Mealey P. O'Connell et al. Should patients with idiopathic dilated cardiomyopathy fail beta-blocker therapy prior to cardiac transplantation? Circulation 1993;88:1-93 (Abstract).